Still Treating Yesterday's Risk? Reconsidering Antiviral Use for Mild‐to‐Moderate <scp>COVID</scp> ‐19 Cases in a Broadly Immune Population
Hadar Mudrik‐Zohar(Tel Aviv University), Steven Y. C. Tong(The Royal Melbourne Hospital), Allen Cheng(Australian Regenerative Medicine Institute), Laura J. Edwards(UNSW Sydney), Susan Morpeth(University of Auckland), Eamon Duffy(Auckland City Hospital), Thomas Hills(Auckland District Health Board), Tim Cutfield(Counties Manukau District Health Board)
Cited by 0
Related Papers
Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management
|Clinical Microbiology Reviews|2015|5.1k
A minimal common outcome measure set for COVID-19 clinical research
|The Lancet Infectious Diseases|2020|1.8k
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19
|JAMA|2020|884
The Epidemiology and Clinical Spectrum of Melioidosis: 540 Cases from the 20 Year Darwin Prospective Study
|PLoS neglected tropical diseases|2010|759